FIELD: biotechnology; medicine.
SUBSTANCE: proposed antibody that specifically binds to SIRPα human to inhibit SIRP bindingα a person with CD47, and an antigen-binding antibody fragment. A pharmaceutical antitumor composition is proposed, containing an effective amount of the proposed antibody or antigen-binding antibody fragment. Proposed is the use of a pharmaceutical composition in combination with an immune checkpoint inhibitor and/or an antibody-like drug that specifically reacts to a tumour antigen to produce ADCC and/or ADCP activity. Proposed methods: a polynucleotide consisting of nucleotide sequences encoding the amino acid sequences of the heavy chain and light chain of the antibody; an expression vector containing the proposed polynucleotide; a host cell for producing an antibody containing a polynucleotide; a method for producing an antibody comprising culturing a host cell and purifying the antibody from the culture; an antibody that specifically binds to SIRPα human to inhibit SIRP bindingα with CB47 obtained by the proposed method.
EFFECT: invention provides an antibody against SIRPα , which can be used as an antitumor agent and as an antitumor agent containing an antibody as an active ingredient.
39 cl, 6 dwg, 41 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RGMa BINDING PROTEIN AND ITS USE | 2016 |
|
RU2809500C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| EMBODIMENTS OF SIRP-ALPHA-4-1BBL FUSION PROTEIN AND METHODS OF USE THEREOF | 2019 |
|
RU2815515C2 |
| INTERLEUKIN-18 OPTIONS AND METHODS FOR THEIR USE | 2018 |
|
RU2797536C2 |
| ANTI-PD-L1 ANTIBODY FOR PD-L1 DETECTION | 2018 |
|
RU2758723C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| ANTIBODY AGAINST LAG-3 | 2017 |
|
RU2744866C2 |
| Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
